Drug General Information (ID: DDI9G3F7SU)
Drug Name			Sargramostim		Drug Info		Blinatumomab		Drug Info
Drug Type		Protein/peptide				Monoclonal antibody
Therapeutic Class		Colony Stimulating Factors				Antineoplastics/Cd19 Monoclonal Antibodies

Mechanism of Sargramostim-Blinatumomab Interaction (Severity Level: Moderate)
Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph
Drug Name		Sargramostim				Blinatumomab
Mechanism		Hematopoietic growth factors				Reduce therapeutic efficacy of hematopoietic growth factors
Key Mechanism Factor 1
		Factor Name		Pharmacodynamics
		Factor Description		Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure.
Mechanism Description		Attenuated pharmacological effects of  Sargramostim when combined with Blinatumomab

Recommended Action
Management		Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.

References
1	Product Information. Granix (tbo-filgrastim). Teva Pharmaceuticals USA, North Wales, PA.
2	Product Information. Leukine (sargramostim). Immunex Corporation, Seattle, WA.
3	Product Information. Stemgen (ancestim) Amgen, Thousand Oaks, CA.